Resources from the same session
Benefits of IO in early and metastatic breast cancer
Presenter: Isabel Pimentel
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast
Who really benefits from IO? Can we identify subsets that benefit and how to measure?
Presenter: Justin Balko
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast
Can we predict and manage toxicity in the real world?
Presenter: Rebecca Dent
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast
What’s on the horizon for immunotherapy for TNBC?
Presenter: Giampaolo Bianchini
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast